Pu Alex, Ramani Gautam, Chen Yi-Ju, Perry James A, Hong Charles C
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States.
Front Drug Discov (Lausanne). 2023;3. doi: 10.3389/fddsv.2023.1127736. Epub 2023 Feb 8.
Pulmonary arterial hypertension (PAH) is characterized by remodeling and narrowing of the pulmonary vasculature which results in elevations of pulmonary arterial pressures. Here, we conducted a genome-wide association study (GWAS) using the UK Biobank, analyzing the genomes of 493 individuals diagnosed with primary pulmonary hypertension, based on ICD-10 coding, compared to 24,650 age, sex, and ancestry-matched controls in a 1:50 case-control design. Genetic variants were analyzed by Plink's firth logistic regression and assessed for association with primary pulmonary hypertension. We identified three linked variants in the gene, which encodes a protooncogene that has been garnering interest as a potential therapeutic target for PAH, that were associated with PAH with genome wide significance, one (rs192449585) of which lies in the promoter region of the gene. We also identified 15 linked variants in the gene. These results provide genetic evidence supporting the role of inhibitors as a potential therapeutic option for PAH.
肺动脉高压(PAH)的特征是肺血管重塑和狭窄,导致肺动脉压力升高。在此,我们利用英国生物银行进行了一项全基因组关联研究(GWAS),基于国际疾病分类第10版(ICD - 10)编码,分析了493名被诊断为原发性肺动脉高压患者的基因组,并与24650名年龄、性别和血统匹配的对照进行了1:50病例对照设计。通过Plink的费舍尔逻辑回归分析基因变异,并评估其与原发性肺动脉高压的关联。我们在该基因中鉴定出三个连锁变异,该基因编码一种原癌基因,作为PAH的潜在治疗靶点一直备受关注,其中一个(rs192449585)位于该基因的启动子区域,这些变异与PAH具有全基因组显著性关联。我们还在该基因中鉴定出15个连锁变异。这些结果提供了遗传证据,支持抑制剂作为PAH潜在治疗选择的作用。